Sure Spare me Greg Why not ? Wish i could have

New Post Public Reply Private Reply Replies (1) Message Board
GREGG THE GREEK hedge_fun #1475
Sure


Quote:
Spare me Greg


Why not ? Wish i could have been sparred a lot of BS too. But since i'm not a classless clown accusing everyone of deceitful behavior all the time, i'll spare you.



As far as this goes....


Quote:
YOU WERE POSTING A FULL SALVAGE PERMIT


that is what i believed. It surely does not make me a scam artist buying PP shares and selling them while i'm pumping and telling others to buy. Which is what the clown has said many times. I love the written word too. Me, sharing my opinion on a message board and defending my investment is not the same as someone taking over the board and posting all kinds of BS.

You are going to tell me that everything else the defendant posted was true except for one or two items ? LOL You obviously have not gone back to read everything he posted. For starters, calling those like myself pumpers who are doing so to sell into it, to trap people is just one example of another misstatement. I call the state and he responds " no call was made " how the f.k could he know ? LOL Oh and btw, the permit was out a day or 2 after i called the state and was informed we were " very " close. I spoke w Mary but was immediately told i was lying and when something i posted came to be, it was just ignored.

But i get it, YOU can care less about what he said or didn't so that's all which matters. Only what you care about and only what he cares about. What the rest of us care about is meaningless. Brilliant.

Does the defendant not post his " positive " opinion , over and over, on the stocks he supports and is invested in ? Has he not been wrong w his opinion, over and over ? Again, that is ok ? Or maybe he is buying discounted shares and selling them ???

Yea, i can spare you and he could have sparred us all a lot of bs and himself too. But life is all about choices. When i've made mistakes in the past, i've had to pay for them. Let's see if the judge spares him. The rest is just BS. Do you think not sparring us your opinion will make a difference in the final outcome ? If the judge does nothing to him, is it some sort of victory for you ? If he is found guilty and gets to spend some time in jail for contempt, if he gets fined, do you spare us ? And in the end, was it all worst it for him ? I'd ask if he had a choice would he do it all over again, but i have a feeling being as ignorant as he is, he would.

Truth is, this will play out as it will play out. But i know i'm personally tired of having someone attack me non stop and i know so are a few others. In the end, i could care less too. It's just some self righteous ignoramus who would get his head bashed and keep coming back for more.

Yea, i'll spare you buddy. Just like i've been sparred a lot of bs commentary and the ( ahem ) threats of being called to court. Well, as i proved in my last response to you, i could care less. But it'd be nice to be sparred the waste of my time for some silly conspiracy theory someone " bets" i'm involved with.

Unlike the clown, I did offer to put my money where my mouth is.

Seafarer Exploration (SFRX) Stock Research Links

SFRX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 11

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 9

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 14

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 20

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 21

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 10

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 19

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading

Top 5 Most Recently Viewed Articles

Sera Prognostics to Showcase Innovations at RBC Healthcare Event

Updated Category News Views 112

Sera Prognostics to Showcase Innovations at RBC Healthcare Event Sera Prognostics Inc., known as The Pregnancy Company (NASDAQ: SERA), is focused on enhancing maternal and neonatal health through innovative pregnancy biomarker information. The company has recently announced its participation at an important healthcare event, highlighting its ongoing commitment to improve...

Continue Reading
Unlocking AI Potential: Insights from Netcracker CEO Andrew Feinberg

Updated Category News Views 268

Exciting Keynote at GITEX Global 2024 Netcracker Technology is buzzing with excitement as Andrew Feinberg, the Chairman and CEO, prepares for a pivotal keynote presentation at one of the largest tech events in the world, GITEX Global 2024. This annual technology conference draws innovators, industry leaders, and enthusiasts keen on understanding the future of technology....

Continue Reading
Adherium Empowers COPD and Asthma Management with iCARE Study

Updated Category News Views 147

Adherium's Transformative iCARE Study Results The innovative strides made by Adherium Limited (ASX:ADR) in respiratory health have shown promising outcomes as seen in the iCARE study. This study investigated the effectiveness of their Hailie® Smartinhaler® technology in improving adherence among patients suffering from chronic obstructive pulmonary disease (COPD) and...

Continue Reading
Medius Highlights Impending Finance Challenges Post AI Launch

Updated Category News Views 243

AI Fraud Concerns Elevate in the Finance Sector Medius has unveiled alarming findings indicating that nearly one in three finance professionals are unable to spot AI-generated fake receipts. This revelation surfaces amidst rising fears of fraud escalation following the recent launch of GPT-5.0. With the capabilities of AI continuously improving, finance teams must prepare...

Continue Reading
TD Cowen Sustainably Endorses Abbott Labs with Robust Price Target

Updated Category News Views 59

TD Cowen Affirms Buy Rating on Abbott Laboratories TD Cowen has reaffirmed its Buy rating on Abbott Laboratories (NYSE: ABT), maintaining a price target of $130.00 for the healthcare company's shares. This positive stance hinges on expectations that Abbott's upcoming third-quarter results will either meet or surpass current market predictions, allowing the company to...

Continue Reading